Ku ya 22 Kanama 2025, Datopotamab deruxtecan (Dato-DXd; Datroway) yemerewe mu Bushinwa kuvura abarwayi bakuru bafite kanseri y'ibere idakira cyangwa idafite hormone receptor–positive, HER2-negative (immunohistochemistry [IHC] 0, IHC 1+, cyangwa IHC 2+/in situ hybridization [ISH] negative) babanje guhabwa ubuvuzi bw'imisemburo ndetse nibura umurongo umwe wa chemotherapy mu buryo bugezweho.
Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.
Nimero ya Terefone: 4008803716
Indangamuntu ya WeChat: 17801183037
Email：myimmnet@163.com
Uku kwemezwa gushingiye ku bisubizo byiza by’ubushakashatsi ku rwego rw’isi bwa Phase III bwa TROPION-Breast01. Inyigo ku rwego rw’isi, icyiciro cya gatatu, ifunguye, kandi yakozwe ku buryo butaziguye ya TROPION-Breast01 yasuzumye antigen y’uturemangingo twa trophoblast surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) ugereranije n’uburyo umushakashatsi yahisemo imiti ya chimiotherapie (ICC) muri kanseri y’ibere ya receptor-positive/human epidermal growth factor 2-negative (HR+/HER2–).
Abarwayi bashyizwe muri Dato-DXd (n = 365) cyangwa ICC (n = 367). Dato-DXd yagabanyije cyane ibyago byo gukomeza cyangwa gupfa ugereranije na ICC (PFS by BICR hazard ratio [HR], 0.63 [95% CI, 0.52 kugeza 0.76]; P < .0001). Inyungu ihoraho ya PFS yagaragaye mu matsinda mato. Nubwo amakuru ya OS atari yageze ku rwego rwo hejuru, hagaragaye uburyo Dato-DXd yakunze gukoreshwa (HR, 0.84 [95% CI, 0.62 kugeza 1.14]). Igipimo cy’ingaruka mbi zijyanye n’ubuvuzi (TRAEs) zo mu rwego rwa ≥3 hamwe na Dato-DXd cyari hasi ugereranije na ICC (20.8% v 44.7%). Indwara za TRAE zikunze kugaragara cyane (icyiciro icyo ari cyo cyose; icyiciro ≥3) zari isesemi (51.1%; 1.4%) na stomatitis (50%; 6.4%) hamwe na Dato-DXd na neutropenia (itsinda, 42.5%; 30.8%) hamwe na ICC.
Abarwayi bakiraga Dato-DXd bagize iterambere rikomeye kandi rifite akamaro mu mibare mu buvuzi muri PFS ndetse n'umutekano wabo urushaho kuba mwiza kandi ugenzurwa, ugereranije na ICC.
Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.
Nimero ya Terefone: 4008803716
Indangamuntu ya WeChat: 17801183037
Email：myimmnet@163.com
Igihe cyo kohereza: Kanama-26-2025